Monopar Therapeutics Inc
MNPR57.750USD
+0.870+1.53%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
384.78MValor de mercado
PerdaP/L TTM
Mais detalhes de Monopar Therapeutics Inc Empresa
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Informações de Monopar Therapeutics Inc
Código da empresaMNPR
Nome da EmpresaMonopar Therapeutics Inc
Data de listagemDec 19, 2019
CEORobinson (Chandler D)
Número de funcionários16
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 19
Endereço1000 Skokie Blvd Ste 350
CidadeWILMETTE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal60091-1146
Telefone18473880349
Sitehttps://www.monopartx.com/
Código da empresaMNPR
Data de listagemDec 19, 2019
CEORobinson (Chandler D)
Executivos da empresa Monopar Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
148.53K
+62945.00%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
+2589.00%
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
148.53K
+62945.00%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
+2589.00%
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: seg, 2 de fev
Atualizado em: seg, 2 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
19.26%
Adage Capital Management, L.P.
9.86%
Gem Pharmaceuticals LLC
9.14%
RA Capital Management, LP
7.65%
AstraZeneca PLC
5.80%
Outro
48.28%
Investidores
Investidores
Proporção
Janus Henderson Investors
19.26%
Adage Capital Management, L.P.
9.86%
Gem Pharmaceuticals LLC
9.14%
RA Capital Management, LP
7.65%
AstraZeneca PLC
5.80%
Outro
48.28%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
28.96%
Hedge Fund
19.01%
Corporation
14.94%
Investment Advisor
10.84%
Venture Capital
9.00%
Individual Investor
6.75%
Research Firm
0.24%
Pension Fund
0.07%
Bank and Trust
0.06%
Outro
10.12%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
123
4.56M
68.20%
+926.42K
2025Q3
99
3.34M
50.46%
+135.23K
2025Q2
76
5.07M
82.91%
-355.61K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
1.29M
19.26%
+115.00K
+9.81%
Sep 30, 2025
Adage Capital Management, L.P.
659.20K
9.86%
+60.00K
+10.01%
Sep 30, 2025
Gem Pharmaceuticals LLC
611.08K
9.14%
--
--
Apr 04, 2025
RA Capital Management, LP
511.21K
7.65%
--
--
Sep 30, 2025
AstraZeneca PLC
387.33K
5.8%
+387.33K
--
Oct 23, 2024
The Vanguard Group, Inc.
208.22K
3.12%
+121.73K
+140.75%
Sep 30, 2025
Wellington Management Company, LLP
231.46K
3.46%
+231.46K
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
182.63K
2.73%
-1.34K
-0.73%
Sep 30, 2025
Deerfield Management Company, L.P.
159.76K
2.39%
+159.76K
--
Sep 30, 2025
Saturn V Capital Management LP
155.37K
2.33%
+155.37K
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proporção0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.05%
Vanguard US Momentum Factor ETF
Proporção0.04%
iShares Russell 2000 Growth ETF
Proporção0.02%
Proshares Ultra Russell 2000
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
iShares Russell 2000 ETF
Proporção0.01%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Data
Data ex-dividendo
Tipo
Proporção
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
